A Phase 2 randomized open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Head And Neck Squamous Cell Carcinoma
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Have histologically confirmed recurrent (not amenable to curative treatment with local and/or systemic therapies) or metastatic (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, and/or larynx that is considered incurable by local therapies. 2) Have experienced disease progression at any time during or after treatment with a platinum-containing (eg, carboplatin or cisplatin) regimen with or without cetuximab. 3) Have disease progression on or after treatment with an anti-PD-1/PD-L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
You may not be eligible for this study if the following are true:
-
1) Has carcinoma of the nasopharynx, salivary gland, unknown primary origin, or nonsquamous histologies as primary tumors. 2) Has a history of re-irradiation to any head and neck sites of disease including the cervical, infraclavicular or supraclavicular lymph nodes for head and neck cancer. 3) Has disease that is suitable for local therapy administered with curative intent.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
